skip to main content

Potassium Binders and RASi — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateElectrolyte DisordersPotassium Binders and RASiESENeph

A 55-year-old woman with diabetes and CKD G3b (eGFR 38 mL/min/1.73m2) develops moderate hyperkalaemia (K+ 5.9 mmol/L) while on Ramipril 10 mg and Dapagliflozin. She was started on Patiromer 3 weeks ago which has controlled her potassium at 5.0-5.2 mmol/L. What is the main advantage of potassium binders like Patiromer or Sodium Zirconium Cyclosilicate (SZC)?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — They enable continuation of renoprotective RASi/SGLT2i/nsMRA therapy by controlling hyperkalaemia

The primary advantage of newer potassium binders (Patiromer and SZC) is enabling patients to remain on guideline-directed renoprotective therapies (RASi, SGLT2i, nsMRA) that commonly cause hyperkalaemia. KDIGO 2024 discusses the role of potassium binders in this context. Without these agents, patients would need dose reduction or cessation of renoprotective drugs, losing their kidney and cardiovascular benefits. Dietary restriction and monitoring remain important.

Reference: KDIGO 2024 – CKD Guideline; Bakris et al 2015 – Patiromer Trial, JAMA